Key facts
- This page summarizes William E. Delaney IV's Form 4 filing for ASSEMBLY BIOSCIENCES, INC. (ASMB).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 01 Apr 2025, 16:05.
William E. Delaney IV - 29 Mar 2025 Form 4 Insider Report for ASSEMBLY BIOSCIENCES, INC. (ASMB)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- ASMB
- Reported as of
- 29 Mar 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Apr 2025, 16:05:11 UTC
- Prior SEC filing
- 01 May 2024
- Next SEC filing
- 31 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ John O. Gunderson, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
William E. Delaney IV filed Form 4 for ASSEMBLY BIOSCIENCES, INC. (ASMB) on 01 Apr 2025.
Change
- Previous filing in this sequence was filed on 01 May 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ASMB
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 16,733
- Date
- 29 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ASMB
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +25,500
- Change %
- Price
- $0.000000
- Shares after
- 25,500
- Date
- 29 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,500
- Exercise price
- $10.62
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Includes 208 shares acquired under the Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan on each of November 14, 2023, May 14, 2024 and November 14, 2024.
Footnote F2
Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, March 29, 2026; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2036.